<!DOCTYPE html>
<html lang="en-us">
  <head><script src="/livereload.js?mindelay=10&amp;v=2&amp;port=1313&amp;path=livereload" data-no-instant defer></script>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
    
    <title>Retatrutide | Affinity Peptides</title>
    <meta name="viewport" content="width=device-width,minimum-scale=1">
    <meta name="description" content="Overview
Retatrutide is an investigational triple-agonist peptide designed to target three key metabolic hormone receptors involved in weight regulation and glucose control:

GLP-1 (glucagon-like peptide-1)
GIP (glucose-dependent insulinotropic polypeptide)
Glucagon receptor

This multi-receptor approach is intended to improve metabolic flexibility, enhance fat loss, and preserve lean mass more effectively than single-pathway therapies.

Mechanism of Action
Retatrutide activates:

  
      
          Receptor
          Function
      
  
  
      
          GLP-1
          Reduces appetite, slows gastric emptying, increases insulin secretion
      
      
          GIP
          Enhances insulin response and nutrient partitioning
      
      
          Glucagon
          Increases energy expenditure and fat oxidation
      
  

By stimulating all three pathways, Retatrutide produces a synergistic metabolic effect that promotes weight loss while supporting glycemic control.">
    <meta name="generator" content="Hugo 0.154.5">
    
    
    
      <meta name="robots" content="noindex, nofollow">
    
    

    
<link rel="stylesheet" href="/ananke/css/main.min.css" >




    


    
      

    

    

    
      <link rel="canonical" href="http://localhost:1313/peptides/retatrutide/">
    

    
    
    <meta property="og:url" content="http://localhost:1313/peptides/retatrutide/">
  <meta property="og:site_name" content="Affinity Peptides">
  <meta property="og:title" content="Retatrutide">
  <meta property="og:description" content="Overview Retatrutide is an investigational triple-agonist peptide designed to target three key metabolic hormone receptors involved in weight regulation and glucose control:
GLP-1 (glucagon-like peptide-1) GIP (glucose-dependent insulinotropic polypeptide) Glucagon receptor This multi-receptor approach is intended to improve metabolic flexibility, enhance fat loss, and preserve lean mass more effectively than single-pathway therapies.
Mechanism of Action Retatrutide activates:
Receptor Function GLP-1 Reduces appetite, slows gastric emptying, increases insulin secretion GIP Enhances insulin response and nutrient partitioning Glucagon Increases energy expenditure and fat oxidation By stimulating all three pathways, Retatrutide produces a synergistic metabolic effect that promotes weight loss while supporting glycemic control.">
  <meta property="og:locale" content="en_us">
  <meta property="og:type" content="article">
    <meta property="article:section" content="peptides">

  <meta itemprop="name" content="Retatrutide">
  <meta itemprop="description" content="Overview Retatrutide is an investigational triple-agonist peptide designed to target three key metabolic hormone receptors involved in weight regulation and glucose control:
GLP-1 (glucagon-like peptide-1) GIP (glucose-dependent insulinotropic polypeptide) Glucagon receptor This multi-receptor approach is intended to improve metabolic flexibility, enhance fat loss, and preserve lean mass more effectively than single-pathway therapies.
Mechanism of Action Retatrutide activates:
Receptor Function GLP-1 Reduces appetite, slows gastric emptying, increases insulin secretion GIP Enhances insulin response and nutrient partitioning Glucagon Increases energy expenditure and fat oxidation By stimulating all three pathways, Retatrutide produces a synergistic metabolic effect that promotes weight loss while supporting glycemic control.">
  <meta itemprop="wordCount" content="238">
  <meta name="twitter:card" content="summary">
  <meta name="twitter:title" content="Retatrutide">
  <meta name="twitter:description" content="Overview Retatrutide is an investigational triple-agonist peptide designed to target three key metabolic hormone receptors involved in weight regulation and glucose control:
GLP-1 (glucagon-like peptide-1) GIP (glucose-dependent insulinotropic polypeptide) Glucagon receptor This multi-receptor approach is intended to improve metabolic flexibility, enhance fat loss, and preserve lean mass more effectively than single-pathway therapies.
Mechanism of Action Retatrutide activates:
Receptor Function GLP-1 Reduces appetite, slows gastric emptying, increases insulin secretion GIP Enhances insulin response and nutrient partitioning Glucagon Increases energy expenditure and fat oxidation By stimulating all three pathways, Retatrutide produces a synergistic metabolic effect that promotes weight loss while supporting glycemic control.">

	
  </head><body class="ma0 avenir bg-near-white development is-page is-page page-Retatrutide">
    
   
  

  <header>
    <div class="bg-black">
      <nav class="pv3 ph3 ph4-ns" role="navigation">
  <div class="flex-l center items-center justify-between">
    <a href="/" class="f3 fw2 hover-white white-90 dib no-underline">
      
        Affinity Peptides
      
    </a>
    <div class="flex-l items-center">
      

      
      <div class="ananke-socials"></div>

    </div>
  </div>
</nav>

    </div>
  </header>



    <main class="pb7" role="main">
      
  

  <article class="page-Retatrutide flex-l mw7 center ph3 flex-wrap justify-between">
    <header class="mt4 w-100">
      <aside class="instapaper_ignoref b helvetica tracked ttu">
          
        Peptide Research Library
      </aside><div id="sharing" class="mt3 ananke-socials"></div>
<h1 class="f1 athelas mt3 mb1">Retatrutide</h1>
      
      
      

      
      
    </header>
    <div class="nested-copy-line-height lh-copy serif f4 nested-links mid-gray pr4-l w-100-l"><h2 id="overview">Overview</h2>
<p>Retatrutide is an investigational triple-agonist peptide designed to target three key metabolic hormone receptors involved in weight regulation and glucose control:</p>
<ul>
<li>GLP-1 (glucagon-like peptide-1)</li>
<li>GIP (glucose-dependent insulinotropic polypeptide)</li>
<li>Glucagon receptor</li>
</ul>
<p>This multi-receptor approach is intended to improve metabolic flexibility, enhance fat loss, and preserve lean mass more effectively than single-pathway therapies.</p>
<hr>
<h2 id="mechanism-of-action">Mechanism of Action</h2>
<p>Retatrutide activates:</p>
<table>
  <thead>
      <tr>
          <th>Receptor</th>
          <th>Function</th>
      </tr>
  </thead>
  <tbody>
      <tr>
          <td>GLP-1</td>
          <td>Reduces appetite, slows gastric emptying, increases insulin secretion</td>
      </tr>
      <tr>
          <td>GIP</td>
          <td>Enhances insulin response and nutrient partitioning</td>
      </tr>
      <tr>
          <td>Glucagon</td>
          <td>Increases energy expenditure and fat oxidation</td>
      </tr>
  </tbody>
</table>
<p>By stimulating all three pathways, Retatrutide produces a synergistic metabolic effect that promotes weight loss while supporting glycemic control.</p>
<hr>
<h2 id="clinical-evidence">Clinical Evidence</h2>
<p>Phase 2 human clinical trials demonstrated:</p>
<ul>
<li>Significant reductions in body fat</li>
<li>Improved insulin sensitivity</li>
<li>Preservation of lean tissue compared to GLP-1â€“only drugs</li>
</ul>
<p>In several studies, subjects achieved double-digit percentage reductions in total body weight over short study periods.</p>
<hr>
<h2 id="research-context">Research Context</h2>
<p>Triple-agonist peptides represent the next generation of metabolic therapeutics. Retatrutide builds upon earlier GLP-1 drugs (such as semaglutide and tirzepatide) by adding a glucagon receptor component, increasing fat oxidation and metabolic rate.</p>
<hr>
<h2 id="safety-considerations">Safety Considerations</h2>
<p>Retatrutide remains an investigational compound. Reported side effects in clinical trials include:</p>
<ul>
<li>Nausea</li>
<li>Gastrointestinal discomfort</li>
<li>Appetite suppression</li>
</ul>
<p>Long-term safety continues to be evaluated in ongoing clinical research.</p>
<hr>
<h2 id="sources">Sources</h2>
<ul>
<li>New England Journal of Medicine</li>
<li>PubMed clinical trial registry</li>
<li>Eli Lilly phase-2 metabolic trial data</li>
</ul>
<p>(Full citations are updated as trials are published.)</p>
<hr>
<p><em>This page is intended for educational and scientific reference only.</em></p>
<ul class="pa0">
  
</ul>

      
    </div></article>

    </main>
    <footer class="bg-black bottom-0 w-100 pa3" role="contentinfo">
  <div class="flex justify-between">
  <a class="f4 fw4 hover-white white-70 dn dib-ns pv2 ph3 no-underline" href="http://localhost:1313/" >
    &copy;  Affinity Peptides 2026 
  </a>
    <div><div class="ananke-socials"></div>
</div>
  </div>
</footer>

  </body>
</html>
